FDG-Positron Emission Tomography Clinical Trials
7 recruitingProcedure
Phase 25Phase 13
Showing 1–7 of 7 trials
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Non-Squamous Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)42 enrolled34 locationsNCT05198830
Recruiting
Phase 2
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)153 enrolled108 locationsNCT06317662
Recruiting
Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology474 enrolled101 locationsNCT06632977
Recruiting
Phase 2
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Carcinoma
Northwestern University125 enrolled6 locationsNCT06244004
Recruiting
Phase 1
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+3 more
University of Washington56 enrolled1 locationNCT04231877
Recruiting
Phase 1Phase 2
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Mantle Cell Lymphoma
OHSU Knight Cancer Institute27 enrolled1 locationNCT06357676
Recruiting
Phase 1
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center24 enrolled1 locationNCT04780568